Shots:

• The P-III CheckMate -915 study involves assessing of Opdivo (240mg- IV- q2w) in combination with Yervoy (1 mg/kg- q6w) vs Opdivo (480mg- q4w) as monothx. as the adjuvant therapy in 1-943 patients who have had complete surgical removal of stage IIIb/c/d or stage IV melanoma
• The P-III CheckMate -915 study did not meet its 1EPs of recurrence-free survival in patients with tumors PD-L1 <1% expression. The study will continue to assess 1EPs of RFS in IIT population- recommended by the Data Monitoring Committee
• Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while Yervoy is mAb targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) thus blocking its interaction with its ligands- CD80/CD86

Click here to­ read full press release/ article 

Ref: BMS | Image: BMS